| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Columbia University College of Physicians and Surgeons (Dr. Marder), New York, NY; the University of Rochester (Drs. Zhao, Kieburtz, and Shoulson, and E. Kayson and C. Orme), Rochester, NY; Boston University (Dr. Myers), Boston, MA; Harvard University (Drs. Cudkowicz and Penney), Cambridge, MA; the University of Iowa (Dr. Paulsen), Iowa City; and Indiana University (Dr. Siemers), Bloomington.
Address correspondence and reprint requests to Dr. Karen Marder, G.H. Sergievsky Center, 630 West 168th Street, New York, NY 10032.
OBJECTIVE: To determine the rate of functional decline in a large cohort of patients with Huntington’s disease (HD) followed at 43 sites by the Huntington Study Group (HSG).
METHODS: The annual rate of functional decline was measured using the Total Functional Capacity Scale (TFC) and the Independence Scale (IS) in 960 patients with definite HD followed prospectively for a mean of 18.3 months. All patients were rated with the Unified Huntington’s Disease Rating Scale (UHDRS). Sample size calculations for hypothetical clinical trials were calculated.
RESULTS: A factor analysis of the UHDRS at baseline yielded 15 factors accounting for 77% of the variance. The TFC score declined at a rate of 0.72 units/year (standard error [SE] 0.04) and the IS score declined at a rate of 4.52 units/year (SE 0.23). Lower TFC score at baseline, indicating more severe impairment, was associated with less rapid annual decline in TFC score, perhaps reflecting the floor effect of the scale. The annual rate of decline for 575 patients with baseline TFC scores of 7 to 13 was 0.97 (SE 0.06), was 0.38 (SE 0.08) for 270 patients with baseline TFC scores of 3 to 6, and was 0.06 (SE 0.1) for 101 patients with TFC scores of 0 to 2. In multivariate analysis (n = 960), longer disease duration and better cognitive status at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology was the only factor associated with more rapid decline on the IS score. Age at onset of HD, sex, weight, and education did not affect decline on either score.
CONCLUSIONS: The comparable rates of decline on the TFC and the IS scores with other published studies suggest that these estimates of functional decline are representative of HD patients who are evaluated at HSG research sites. In longitudinal analysis, longer disease duration and better neuropsychological performance at baseline were associated with a less rapid rate of decline in TFC score, whereas depressive symptomatology at baseline was associated with a more rapid decline in the IS score. These rates of functional decline and the covariates that modify them should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease.
Key words: Huntington’s disease—Functional decline
This article has been cited by other articles:
|
|
 |
|
  K. Marder, H. Zhao, S. Eberly, C. M. Tanner, D. Oakes, I. Shoulson, and On behalf of the Huntington Study Group Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS Research Participants Neurology, August 4, 2009; 73(5): 385 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Naarding, J. G.E. Janzing, P. Eling, S. van der Werf, and B. Kremer Apathy Is Not Depression in Huntington's Disease J Neuropsychiatry Clin Neurosci, August 1, 2009; 21(3): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Leoni, C. Mariotti, S. J. Tabrizi, M. Valenza, E. J. Wild, S. M. D. Henley, N. Z. Hobbs, M. L. Mandelli, M. Grisoli, I. Bjorkhem, et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease Brain, November 1, 2008; 131(11): 2851 - 2859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Rosas, D. H. Salat, S. Y. Lee, A. K. Zaleta, V. Pappu, B. Fischl, D. Greve, N. Hevelone, and S. M. Hersch Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity Brain, April 1, 2008; 131(4): 1057 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ramirez-Montealegre and D. A. Pearce Imaging of late infantile neuronal ceroid lipofuscinosis: A clinical rating scale Neurology, August 7, 2007; 69(6): 503 - 504. [Full Text] [PDF]
|
|
|
|
|
|
M.-N. W. Witjes-Ane, B. Mertens, J. P.P. van Vugt, A.-C. Bachoud-Levi, G.-J. B. van Ommen, and R. A.C. Roos Longitudinal Evaluation of "Presymptomatic" Carriers of Huntington's Disease J Neuropsychiatry Clin Neurosci, August 1, 2007; 19(3): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Langbehn, J. S. Paulsen, and The Huntington Study Group Predictors of diagnosis in Huntington disease Neurology, May 15, 2007; 68(20): 1710 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosenblatt, K. -Y. Liang, H. Zhou, M. H. Abbott, L. M. Gourley, R. L. Margolis, J. Brandt, and C. A. Ross The association of CAG repeat length with clinical progression in Huntington disease Neurology, April 11, 2006; 66(7): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Puri, B. R. Leavitt, M. R. Hayden, C. A. Ross, A. Rosenblatt, J. T. Greenamyre, S. Hersch, K. S. Vaddadi, A. Sword, D. F. Horrobin, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial Neurology, July 26, 2005; 65(2): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Strand, A. K. Aragaki, D. Shaw, T. Bird, J. Holton, C. Turner, S. J. Tapscott, S. J. Tabrizi, A. H. Schapira, C. Kooperberg, et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker Hum. Mol. Genet., July 1, 2005; 14(13): 1863 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M Gaba, K. Zhang, K. Marder, C. B Moskowitz, P. Werner, and C. N Boozer Energy balance in early-stage Huntington disease Am. J. Clinical Nutrition, June 1, 2005; 81(6): 1335 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.K. Ho, B.J. Sahakian, R.G. Brown, R.A. Barker, J.R. Hodges, M.-N. Ane, J. Snowden, J. Thompson, T. Esmonde, R. Gentry, et al. Profile of cognitive progression in early Huntington's disease Neurology, December 23, 2003; 61(12): 1702 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Huntington Study Group Dosage effects of riluzole in Huntington's disease: A multicenter placebo-controlled study Neurology, December 9, 2003; 61(11): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mahant, E.A. McCusker, K. Byth, and S. Graham Huntington's disease: Clinical correlates of disability and progression Neurology, October 28, 2003; 61(8): 1085 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verbessem, J. Lemiere, B. O. Eijnde, S. Swinnen, L. Vanhees, M. Van Leemputte, P. Hespel, and R. Dom Creatine supplementation in Huntington's disease: A placebo-controlled pilot trial Neurology, October 14, 2003; 61(7): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Rosas, W. J. Koroshetz, Y. I. Chen, C. Skeuse, M. Vangel, M. E. Cudkowicz, K. Caplan, K. Marek, L. J. Seidman, N. Makris, et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis Neurology, May 27, 2003; 60(10): 1615 - 1620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Squitieri, C. Gellera, M. Cannella, C. Mariotti, G. Cislaghi, D. C. Rubinsztein, E. W. Almqvist, D. Turner, A.-C. Bachoud-Levi, S. A. Simpson, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course Brain, April 1, 2003; 126(4): 946 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bilney, M. E. Morris, and A. Perry Effectiveness of Physiotherapy, Occupational Therapy, and Speech Pathology for People with Huntington's Disease: A Systematic Review Neurorehabil Neural Repair, March 1, 2003; 17(1): 12 - 24. [Abstract] [PDF]
|
|
|
|
|
|
L. Djousse, B. Knowlton, L. A. Cupples, K. Marder, I. Shoulson, and R. H. Myers Weight loss in early stage of Huntington's disease Neurology, November 12, 2002; 59(9): 1325 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Hauser, S. Furtado, C. R. Cimino, H. Delgado, S. Eichler, S. Schwartz, D. Scott, G. M. Nauert, E. Soety, V. Sossi, et al. Bilateral human fetal striatal transplantation in Huntington's disease Neurology, March 12, 2002; 58(5): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Brown, L. Redondo-Verge, J. R. Chacon, M. L. Lucas, and S. Channon Dissociation between intentional and incidental sequence learning in Huntington's disease Brain, November 1, 2001; 124(11): 2188 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reilmann, F. Kirsten, L. Quinn, H. Henningsen, K. Marder, and A. M. Gordon Objective assessment of progression in Huntington's disease: A 3-year follow-up study Neurology, September 11, 2001; 57(5): 920 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease Neurology, August 14, 2001; 57(3): 397 - 404. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
